Lupin's Glumetza Settlement Costs But Spiriva Offers Hope
Talks On For Revlimid Settlement
Executive Summary
Lupin’s Q2 was a tale of three generics settlements – on Glumetza, which is still a commercial win despite the quarter-billion dollar outgo so far, on Spiriva, which will likely lead to happy tidings next fiscal year, and on Revlimid, on which the company has yet to make up its mind.
You may also be interested in...
Ryaltris US Debut Plan, Generic Spiriva Fuel Buoyant Glenmark Outlook
Glenmark makes buoyant sales projections for Ryaltris, which is set for US debut in the first quarter of FY23 and has also seen launch momentum in several international markets. The rhinitis therapy along with generic Spiriva are seen as pivotal to drive the Indian company's growth in Europe.
Ryaltris US Debut Plan, Generic Spiriva Fuel Buoyant Glenmark Outlook
Glenmark makes buoyant sales projections for Ryaltris, which is set for US debut in the first quarter of FY23 and has also seen launch momentum in several international markets. The rhinitis therapy along with generic Spiriva are seen as pivotal to drive the Indian company's growth in Europe.
Lupin Expects Exeltis Partnership To Boost Solosec
Lupin is hoping that a newly-struck partnership with women’s health specialist Exeltis will improve the fortunes of its Solosec (secnidazole) bacterial vaginosis and trichomoniasis treatment in the US.